DUBLIN--(BUSINESS WIRE)--The "Drug Discovery Services Market by Process (Target Selection, Validation, Lead Optimization), Type (Medicinal Chemistry, DMPK), Drug Type (Biologics, Small Molecules), Therapeutic (Oncology, Neurology), Company (Tier 1, 2, 3) - Global Forecast to 2025" report has been added to ResearchAndMarkets.com's offering.

Drug discovery services market to register a CAGR of 12.1% from 2020 to 2025.

The growth of the industry is driven primarily by factors such as growing R&D expenditure in the pharmaceutical & biopharmaceutical industry, increasing demand for outsourcing analytical testing and clinical trial services, initiatives for research on rare diseases and orphan drugs, and focus on drug discovery. Growth in the biologics market and patent expiries will further provide opportunities in the drug discovery services industry. Developing economies are expected to offer a wide range of growth opportunities for players in the market.

The Hit-to-Lead process segment is anticipated to grow at the fastest growth rate during the forecast period.

Based on the process, the drug discovery services market is segmented into target selection, target validation, hit-to-lead identification, lead optimization, and candidate validation. Hit-to-lead identification process is anticipated to be the fastest-growing segment due to the high outsourcing of these services to CROs by the pharmaceutical companies and the emerging advanced technologies for high-throughput screening (HTS) and H2L as well as reductions in development time.

Medicinal Chemistry segment is estimated to account for the largest share of the drug discovery services market in 2020.

Based on type, the drug discovery services market is segmented into medicinal chemistry services, biology services, and drug metabolism and pharmacokinetics (DMPK). The medicinal chemistry services segment is estimated to account for the largest share of the drug discovery services market due to the widespread application of medicinal chemistry in various phases of preclinical drug discovery to deliver robust candidates.

Oncology segment is anticipated to grow at the fastest growth rate during the forecast period.

Based on the therapeutic area, the drug discovery services market is segmented into oncology, cardiovascular diseases, neurology, infectious and immune system diseases, digestive system diseases, and other therapeutic areas. Of all these therapeutic segments, oncology will grow at the fastest CAGR in the drug discovery services market in 2019. The high growth of the oncology segment can be attributed to factors such as the increasing number of patients who have cancer, the subsequent increase in the demand for cancer therapies and the growing R&D expenditure by pharmaceutical companies in this therapeutic area.

North America is expected to dominate the drug discovery services market in 2020.

North America, which includes the US and Canada, is estimated to account for the largest share of the drug discovery services market. The large share of this region can primarily be attributed to the presence of well-established CROs; rising R&D expenditure by pharmaceutical & biopharmaceutical companies and the availability of latest techniques, instruments, and facilities for drug discovery research are driving the growth of this region.

Reasons to Buy the Report:

Key Topics Covered:

1 Introduction

1.1 Objectives of the Study

1.2 Market Definition

1.3 Market Scope

1.4 Currency

1.5 Limitations

1.6 Stakeholders

2 Research Methodology

2.1 Research Data

2.2 Market Size Estimation

2.3 Market Breakdown and Data Triangulation

2.4 Assumptions for the Study

3 Executive Summary

4 Premium Insights

4.1 Drug Discovery Services Market Overview

4.2 North America: Market, By Drug Type & Country (2020)

4.3 Market: Geographic Growth Opportunities

5 Market Overview

5.1 Introduction

5.2 Market Dynamics

5.2.1 Drivers

5.2.2 Restraints

5.2.3 Opportunities

5.2.4 Trends

6 Drug Discovery Services Market, By Process

6.1 Introduction

6.2 Target Selection

6.3 Target Validation

6.4 Hit-To-Lead Identification

6.5 Lead Optimization

6.6 Candidate Validation

7 Drug Discovery Services Market, By Type

7.1 Introduction

7.2 Medicinal Chemistry Services

7.3 Biology Services

7.4 Drug Metabolism & Pharmacokinetics

8 Drug Discovery Services Market, By Drug Type

8.1 Introduction

8.2 Small-Molecule Drugs

8.3 Biologic Drugs

9 Drug Discovery Services Market, By Therapeutic Area

9.1 Introduction

9.2 Oncology

9.3 Neurology

9.4 Infectious and Immune System Diseases

9.5 Digestive System Diseases

9.6 Cardiovascular Diseases

9.7 Other Therapeutic Areas

10 Drug Discovery Services Market, By Company Type

10.1 Introduction

10.2 Tier 1 Pharmaceutical Companies

10.3 Tier 2 Pharmaceutical Companies

10.4 Tier 3 Pharmaceutical Companies

11 Drug Discovery Services Market, By Region

11.1 Introduction

11.2 North America

11.3 Europe

11.4 Asia Pacific

11.5 Rest of the World

12 Competitive Landscape

12.1 Overview

12.2 Market Share Analysis

12.3 Competitive Scenario

12.4 Competitive Leadership Mapping

13 Company Profiles

13.1 Laboratory Corporation of America Holdings

13.2 Eurofins Scientific Se

13.3 Charles River Laboratories International

13.4 Evotec SE

13.5 Thermo Fisher Scientific

13.6 Albany Molecular Research, Inc.

13.7 Syngene International Limited

13.8 Jubilant Lifesciences

13.9 Genscript Biotech Corporation

13.10 Piramal Enterprises Limited

13.11 Selvita S.A.

13.12 Aurigene Discovery Technologies

13.13 Domainex Ltd.

13.14 WuXi AppTec

13.15 Chempartner Co., Ltd.

13.16 Frontage Holdings

13.17 Pharmaceutical Product Development, LLC

13.18 Shanghai Medicilon, Inc.

13.19 TCG Lifesciences Pvt. Limited

13.20 Viva Biotech (Shanghai) Ltd.

For more information about this report visit https://www.researchandmarkets.com/r/i0k3fl

Originally posted here:
Global Drug Discovery Services Market is Projected to Reach USD 19.1 Billion By 2025 at a CAGR of 12.1% from 2020 to 2025 - ResearchAndMarkets.com -...